
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Fifty years have witnessed unprecedented progress in the pediatrician's ability to diagnose, treat, and prevent illness. What lies ahead for you and your colleagues? Part One of a three-part series.






